※一部利用できない機能があります
Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
- 資料種別:
- 論文(リポジトリ)
- 責任表示:
- Nakamura, Hideta ; Miyagi, Kazuya ; Otsuki, Mariko ; Higure, Yuuri ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Haranaga, Shusaku ; Tateyama, Masao ; Fujita, Jiro
- 言語:
- 英語
- 出版情報:
- The Japanese Society of Internal Medicine — 一般社団法人 日本内科学会, 2020-11-15
- 著者名:
Nakamura, Hideta Miyagi, Kazuya Otsuki, Mariko Higure, Yuuri Nishiyama, Naoya Kinjo, Takeshi Nakamatsu, Masashi Haranaga, Shusaku Tateyama, Masao Fujita, Jiro - 掲載情報:
- Internal Medicine
- ISSN:
- 1349-7235
0918-2918 - 巻:
- 59
- 通号:
- 22
- 開始ページ:
- 2945
- 終了ページ:
- 2949
- バージョン:
- VoR
- 概要:
- Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19
…
remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
論文 続きを見る - URL:
- http://hdl.handle.net/20.500.12000/47366